title: Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
abstract: Ascites formation in patients with cirrhosis, portal hypertension, or both usually results from hyperdynamic circulatory dysfunction, where the retention of sodium and water is associated with the activation of the sympathetic and renin-angiotensin-aldosterone systems. The presence of ascites indicates the development of liver decompensation. Furthermore, complications seen in conjunction with ascites such as spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic hydrothorax may result in increased morbidity and mortality. Although nonpharmacological, pharmacological, and surgical approaches have been introduced and clinically practiced, their therapeutic effects are still suboptimal or limited by their potential side effects, such as large-volume paracentesis-induced postparacentesis circulatory dysfunction. Herein, we discuss strategies to prevent and properly manage ascites-related complications, including a review of the literature and controlled studies that assess these strategies.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
authors.forename: Shao-Jung
authors.initials: SJ
authors.lastname: Hsu
authors.forename: Hui-Chun
authors.initials: HC
authors.lastname: Huang
mesh_terms: D001201:Ascites / Q000209:etiology / Q000628:therapy*; D006530:Hepatorenal Syndrome / Q000628:therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008236:Lypressin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008879:Midodrine / Q000627:therapeutic use; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D011433:Propranolol / Q000627:therapeutic use; D000077585:Terlipressin
chemical_list: D008236:Lypressin; D008879:Midodrine; D000077585:Terlipressin; D011433:Propranolol